Naoya Yamazaki

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 991 citations · Full text

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

Shogo Kumagai, Yosuke Togashi, Takahiro Kamada et al. · Nature Immunology · 2020 · 785 citations

Cancer Immunosurveillance, Autoimmune Disease, T-regulatory Cell +12

Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

Shogo Kumagai, Shohei Koyama, Kota Itahashi et al. · Cancer Cell · 2022 · 752 citations

Cancer Immunosurveillance, Pd-1 Expression, Medicine +11

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 578 citations

Overall Survival, Binimetinib Versus Vemurafenib, Medicine +7